Lepu Medical Technology (Beijing) Co., Ltd.
300003
株式のランク
#4640
Established in 1999 and headquartered in Beijing, China, Lepu Medical... Established in 1999 and headquartered in Beijing, China, Lepu Medical Technology is a prominent company dedicated to the research, development, production, and sale of a broad spectrum of medical devices, pharmaceuticals, and healthcare services. The company's extensive medical device portfolio primarily focuses on cardiovascular health. This includes interventional cardiology products such as coronary stents, balloons, catheters, guide wires, and related PCI accessories. It also provides solutions for structural heart diseases, like occluders, vascular plugs, delivery systems, and mechanical heart valves. Lepu Medical offers cardiac rhythm management products, including pacemakers, equipment, leads, and electrophysiology systems, alongside products for off-pump coronary artery bypass grafting and peripheral interventional devices such as PTA balloons and guide wires. Beyond cardiovascular applications, their offerings extend to critical care products like vascular access devices, needle-free connectors, blood samplers, and pressure transducers. The company also provides digital subtraction angiography (DSA) systems (both floor and suspended types), in vitro diagnostic (IVD) equipment and biomarkers, hemodialysis catheters and hollow fiber dialyzers, and general surgery instruments including surgical staplers and endo surgery accessories. In the pharmaceutical sector, Lepu Medical manufactures and distributes medications for various conditions. This encompasses a comprehensive range of cardiovascular drugs designed to treat issues like thrombosis, hyperlipidemia, hypertension, angina, and heart failure. Additionally, they produce beta-lactamase antibiotics and antifungal antimicrobial drugs, central nervous system medications (such as painkillers and antidepressants), treatments for gastric/duodenal ulcers and chronic liver disease, respiratory system drugs, hypoproteinemia drugs, and agents that activate blood circulation. Furthermore, Lepu Medical provides a diverse array of healthcare services. These include precision medicine, remote ECG telemonitoring, and specialized consulting and management centers for cardiovascular diseases. The company is also involved in medical science and technology incubation, equity investment, and offers medical financial services. Its service offerings extend to general health consultation, online pharmacy platforms, sales of household medical equipment, smart medical devices, and the operation of specialized hospitals focusing on cardiovascular care. Lepu Medical actively participates in the establishment and co-construction of cardiac catheterization laboratories (Cath Labs).
株価
$1.78
時価総額
$3.29B
変化（1日）
6.19%
変化（1年）
-30.01%
国
CN
取引 Lepu Medical Technology (Beijing) Co., Ltd. (300003)
カテゴリー
Healthcare
Lepu Medical Technology (Beijing) Co., Ltd.（300003）のP/E比率
October 2026 時点のP/E比率 TTM 26.94
Lepu Medical Technology (Beijing) Co., Ltd. の最新の財務報告および株価によると、現在の P/E (TTM) は 26.94 です。2023 年末時点での P/E は 23.68 でした。
Lepu Medical Technology (Beijing) Co., Ltd. の P/E 比率の履歴（2006 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 26.94 | -68.26% |
| 2024 | 84.88 | 258.42% |
| 2023 | 23.68 | 26.07% |
| 2022 | 18.78 | -20.35% |
| 2021 | 23.58 | -12.01% |
| 2020 | 26.80 | -21.04% |
| 2019 | 33.94 | 15.62% |
| 2018 | 29.36 | -36.13% |
| 2017 | 45.97 | 0.31% |
| 2016 | 45.82 | -23.84% |
| 2015 | 60.16 | 31.75% |
| 2014 | 45.66 | 21.35% |
| 2013 | 37.63 | 104.00% |
| 2012 | 18.45 | -21.43% |
| 2011 | 23.48 | -56.69% |
| 2010 | 54.20 | -17.55% |
| 2009 | 65.74 | -42.79% |
| 2008 | 114.92 | -10.24% |
| 2007 | 128.03 | 5.55% |
| 2006 | 121.29 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 33.11 | 22.91% |
US
|
|
| 21.39 | -20.61% |
IE
|
|
| 28.94 | 7.45% |
US
|
|
| 17.34 | -35.64% |
US
|
|
| - | - |
DE
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。